A version of this article was previously published in the Journal of mHealth. The days of cookie-cutter medical education sessions and unengaging, didactic data presentations are–mostly–over. These days, medical education and training programs are all about customization, personalization, and innovation. In this article, we take a look at 10 of the hottest trends in medical education and learning programs. 1. Virtual & Augmented Reality Kicking off the top 10, virtual reality (VR) and augmented reality (AR) are two increasingly used tools for anatomy education and surgical training, o ..read more

CHICAGO–(BUSINESS WIRE)–GE HealthCare (Nasdaq: GEHC) today announced it has entered into an agreement to acquire Intelligent Ultrasound Group PLC’s (Intelligent Ultrasound) clinical artificial intelligence (AI) software business for total consideration of approximately $51 million. Intelligent Ultrasound is a leader in integrated AI-driven image analysis tools designed to make ultrasound smarter and more efficient. GE HealthCare plans to incorporate these solutions across the ultrasound portfolio, strengthening its capabilities with technology that helps improve workflows and enhance ease-of ..read more

SAN MATEO, Calif.–(BUSINESS WIRE)–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the Company through August to support the transition. “We are thrilled to welcome Aaron amid a transformational year for BeiGene as we became a top 15 global oncology innovator by revenue with sustained progress to profitability and one of the most prolific and innovative pip ..read more

OXFORD, England–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) today announced it has reached an agreement to acquire GT Apeiron’s share of its oral CDK7 inhibitor programme, gaining full control of GTAEXS617 (‘617) and all related intellectual property. The monotherapy dose escalation phase of ELUCIDATE is designed to assess the safety, pharmacokinetics and pharmacodynamics of ‘617 in advanced solid tumours. Recruitment for the trial is progressing well with monotherapy dose escalation data on track to readout in the second half of 2024. In late 2024/early 2025, the study will transition to a ..read more

LEXINGTON, Mass.–(BUSINESS WIRE)–Agenus Inc. (NASDAQ: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM). Key Outcomes of the EOP2 Meeting: Dosing Regimen: Agenus gained agreement on the proposed BOT/BA ..read more

RADNOR, Pa.–(BUSINESS WIRE)–Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of epileptic seizures in patients two years of age and older with CDKL5 deficiency disorder (CDD). In November 2022, Marinus and Tenacia Biotechnology entered into a collaboration agreement which granted Tenacia the right to develop and commercialize ganaxolone in Mainland China ..read more

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME) and diabetic retinopathy (DR), respectively, the two leading causes of vision loss in adults with diabetes. Susvimo is the first and only refillable eye implant that provides continuous delivery of a customized formulation of ranibizumab via the Port Delivery Platform. The results build on the primary on ..read more

INDIANAPOLIS–(BUSINESS WIRE)–DecisionRx, Inc., a value-based healthcare company reducing the cost of care by helping individuals eliminate medication failure, announced today a collaboration with AmeriLife Group, LLC (“AmeriLife”), a leading provider of insurance and retirement solutions, to provide Medicare Advantage and Medicare Supplement patients access to its Medication Therapy Optimization (MTO) platform. The DecisionRx MTO platform provides patients and providers with an analysis of which medications work with each patient’s unique genetics, lifestyle, and clinical history. DecisionRx ..read more

SAN FRANCISCO–(BUSINESS WIRE)–Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, today announced the appointment of Cristiana Guiducci, Ph.D., as chief scientific officer. Dr. Guiducci previously served as senior vice president of immunology and oncology research of Nurix Therapeutics and has nearly 20 years of experience in oncology and immunology drug discovery research. “Cristiana brings deep scientific experience in drug discovery and has important expertise in building foundational research teams, identifying drug ..read more

LAUSANNE, Switzerland & SAN DIEGO–(BUSINESS WIRE)–HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Eric Adam, Ph.D. has joined as Chief Operating Officer (COO). With over 25 years of experience in health technology and healthcare sectors, Eric joins HAYA’s team in Lausanne after serving as Global Head of Operations within Neuroscience and Rare Diseases in Pharma Research and Early Development (pRED) at Roche. As COO, Dr. Adam’s will help HAYA streamline operations to support scalable gro ..read more